表面活性剂的性能与应用(Ⅴ)——脂质体及其应用

doi:10.13218/j.cnki.csdc.2014.05.056

摘要/Abstract

摘要： 首先简要介绍了脂质体的概念,总结了脂质体的常用制备方法,然后概述了脂质体的载药特性和靶向原理,列出了几种新型脂质体,最后重点综述了脂质体作为药物载体进行靶向给药的应用实例。

Abstract: The concept of liposome was introduced briefly,and then the preparation methods were summarized.The characteristics of drug carrying and principles of targeting were described,followed by several novel kinds of liposome.Finally,the applications in targeted drug delivery were summarized.

Key words: phospholipid, liposome, drug carrier, preparation, application

中图分类号:

TQ423

苏鹏权, 赵莉, 徐宝财, 周雅文. 表面活性剂的性能与应用(Ⅴ)——脂质体及其应用[J]. 日用化学工业, 2014, 44(5): 252-256.

SU Peng-quan, ZHAO Li, XU Bao-cai, ZHOU Ya-wen. Performance and applications of surfactants (Ⅴ) Liposome and its applications[J]. China Surfactant Detergent & Cosmetics, 2014, 44(5): 252-256.

参考文献

[1] BANGHAM A D,STANDISH M M,WATKINS J C.Diffusion of univalent ions across the lamellae of swollen phospholipids [J].Journal of Molecular Biology,1965,13(1):238-252.
[2] BUDAI M,SZOGYI M.Liposomes as drug carrier systems.Preparation,classification and therapeutic advantages of liposomes [J].Acta Pharmaceutica Hungarica,2001,71(1):114-118.
[3] TORCHILIN V,WEISSIG V.Liposome:A practical approach (Practical approach series)[M].2nd ed.England:Oxford University Press,2003:10-12.
[4] LASIC D D.Liposomes:from physics to applications [M].Netherland:Elsevier Science Publishers,1993:3-7.
[5] LANGSTON M V,RAMPRASAD M P,KARARLI T T,et al.Modulation of the sustained delivery of myelopietin (Leridistim) encapsulated in multivesicular liposomes (Depofoam) [J].Journal of Controlled Release,2003,89(1):87-99.
[6] 赵海霞,郭兴奎,孔德亮,等.脂质体制备技术[J].山东中医药杂志,2000,19(7):435-437.
[7] 陈建雯,马波,林华,等.流感疫苗脂质体干粉制备方法对其免疫原性影响研究[J].南京医科大学学报:自然科学版,2013(7):1019-1023.
[8] 高晶,黄少烈.脂质体的制备方法及其比较[J].中国油脂,2004,29(10):52-54.
[9] 杨文秀.脂质体主动载药的研究与应用进展[J].现代医药卫生,2011,27(17):2647-2648.
[10] ZHIGALTSEV I V,MAURER N,AKHONG Q F,et al.Liposome-encapsulated vincristine,vinblastine and vinorelbine:A comparative study of drug loading and retention [J].Journal of Controlled Release,2005,104(1):103-111.
[11] 高媛媛,张维农.脂质体的制备与检测方法研究进展[J].武汉工业学院学报,2010,29(3):44-52.
[12] 邓意辉,于彬,李焕秋,等.pH梯度法制备阿霉素脂质体[J].沈阳药科大学学报,1997,14(4):239-240.
[13] SANDRA R,ANNA S,GIACOMO M,et al.Synthesis and liposome insertion of a new poly (carboranylalkylthio) porphyrazine to improve potentiality in multiple-approach cancer therapy [J].Journal of the American Chemical Society,2007,129(10):2728-2729.
[14] LI Z,YU L,ZHENG L Q,et al.Studies on crystallinity state of puerarin loaded solid lipid nanoparticles prepared by double emulsion method [J].Journal of Thermal Analysis and Calorimetry,2010,99(2):689-693.
[15] 贾莉,赵辉,刘沛沛.阿霉素脂质体的冻干工艺考察[J].北方药学,2013,10(8):63-64.
[16] MORTAZAVI S M,MOHAMMADABADI M R,KHOSRAVIDARANI K,et al.Preparation of liposomal gene therapy vectors by a scalable method without using volatile solvents or detergents [J].Journal of Biotechnology,2007,129(4):604-613.
[17] GAUR P K,MISHRA S,GUPTA V B,et al.Targeted drug delivery of Rifampicin to the lungs:Formulation,characterization,and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome [J].Drug Development and Industrial Pharmacy,2010,36(6):638-646.
[18] 穆筱梅,梁世强.脂质体的制备方法及其研究进展[J].时珍国医国药,2008,19(7):1784-1786.
[19] 于波涛,张志荣,刘文胜.提高脂质体包封率的方法及其研究进展[J].中国医药工业杂志,2002,33(11):564-568.
[20] 吴芳.脂质体制剂的研究与应用[J].中国医药工业杂志,1999,30(12):564.
[21] 杨莉,成丽,魏于全.脂质体在肿瘤靶向治疗中的应用[J].华西医学,2005,20(2):387-388.
[22] 陆彬.药物新剂型与新技术[M].北京:人民卫生出版社,2005:179.
[23] 曹纯洁.长循环脂质体的研究进展[J].药学实践杂志,2005,23(1):1-3.
[24] 陈静,潘兴国,牛焕义,等.替吉奥胶囊联合奥沙利铂、伊立替康/亚叶酸钙治疗晚期胃癌疗效分析[J].重庆医科大学学报,2011,36(1):1397-1399.
[25] 陈果,彭健,何颖,等.伊立替康长循环脂质体的初步生物学活性研究[J].中国现代医学杂志,2013,23(9):18-22.
[26] VENUGOPALAN P,JAIN S,SANKAR S,et al.pH-sensitive liposomes:mechanism of triggered release to drug and gene delivery prospects [J].Pharmazie,2002,57(10):659-671.
[27] 王潞,赵烽,刘珂.牛蒡子苷及牛蒡子苷元的药理作用研究进展[J].中草药,2008,39(3):467-470.
[28] 武鑫朋,孙李妍,慕宏杰,等.Box-Behnken效应面法优化牛蒡苷pH敏感脂质体处方[J].齐鲁药事,2011,30(11):625-628.
[29] LIU T G,TANG M Z,JIN F G.Thermo-controlled drug-release characteristics and stability of thermo-sensitive liposome of ADM [J].Fourth Mil Med Univ,2002,23:1225-1227.
[30] 杨美燕,李煜蒙,梅兴国.奥沙利铂长循环热敏脂质体的包封率测定及体外释放考察[J].军事医学科学院院刊,2007,31(5):448-450.
[31] 庄宝雄,陈燕铭,张阳德,等.奥沙利铂长循环热敏脂质体的制备与理化性质研究[J].中国现代医学杂志,2011,21(36):4558-4561.
[32] 崔晓波,梁传余.18例原发鼻腔和鼻窦的T/NK淋巴瘤的临床分析[J].临床耳鼻咽喉科杂志,2004,18(11):651-652.
[33] 唐琼兰,刘卫平,李甘地.西南地区鼻和鼻型NK/T细胞淋巴瘤的临床病理特征及预后分析[J].肿瘤,2003,23(5):411-413.
[34] 杨平,林珈好,王玉蓉.盐酸小檗碱前体脂质体的制备及理化性质研究[J].药物研究,2012,2(2):32-33.
[35] 樊祥山.磁性脂质体在肿瘤治疗研究中的应用[J].国外医学:肿瘤学分册,2003,30(2):147-149.
[36] URASAKI Y,LACO G,TAKEBAYASHI Y,et al.Use of camptothecin-resistant mammalian cell activity of the role of topoisomerase in the antiproliferative activity of the indolocarbazole,NB-506,and its topoisomerase binding site [J].Cancer Research,2001,61(2):504.
[37] 凌家俊,古锦辉,谢毅,等.羟基喜树碱磁性脂质体的制备及其靶向性特征试验[J].中国实验方剂学杂志,2012,18(16):19-23.
[38] 何驰,吴婷婷.免疫脂质体在肿瘤治疗中的应用[J].中国肿瘤生物治疗杂志,2012,19(2):215-218.
[39] TAGUCHI T.Review of a new antimetabolic agent 1-hexylcarbamoyl 5-fluorouracil (HCFU) [J].Recent Results in Cancer Research,1980,70:125-132.
[40] 孟胜男,赵希贤,姜翠莲,等.大肠癌特异性卡莫氟免疫脂质体的体外抗癌活性研究[J].沈阳药科大学学报,2003,20(5):370-372.
[41] 王森,欧水平,朱卫丰,等.柔性脂质体在中药经皮给药制剂中的应用[J].中国实验方剂学杂志,2011,17(1):30-34.
[42] 魏向东.氯雷他定致消化道损害1例[C]//2008全国中西医结合皮肤性病学术会议论文汇编.2008:100.
[43] 谢艳萍.氯雷他定柔性脂质体的制备及体外透皮研究[J].中国药师,2012,15(4):445-448.